Freeline Therapeutics Holdings (DB:78F0) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

78F0 Stoklara Genel Bakış

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.

Şirket hakkında

78F0 temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Trading at 30.7% below our estimate of its fair value

Revenue is forecast to grow 60.35% per year

Risk Analizi

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Has less than 1 year of cash runway

Does not have a meaningful market cap (€18M)

+ 1 daha fazla risk

Freeline Therapeutics Holdings plc Rakipler

Medigene

XTRA:MDG1

€31.0m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€60.4m

4SC

DB:VSC

€56.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Freeline Therapeutics Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.23
52 Haftanın En Yüksek Seviyesi	US$13.95
52 Haftanın En Düşük Seviyesi	US$3.12
Beta	0.71
11 Aylık Değişim	0%
3 Aylık Değişim	-92.93%
1 Yıllık Değişim	-98.23%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.85%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	78F0	DE Biotechs	DE Pazar
7D	0%	2.2%	-1.9%
1Y	-98.2%	-9.6%	12.3%

Getiri vs. Endüstri: 78F0 underperformed the German Biotechs industry which returned -23.1% over the past year.

Getiri vs Piyasa: 78F0 underperformed the German Market which returned 5.9% over the past year.

Fiyat Oynaklığı

Is 78F0's price volatile compared to industry and market?
78F0 volatility
78F0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 78F0's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: Insufficient data to determine 78F0's volatility change over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	152	Michael Parini	www.freeline.life

Freeline Therapeutics Holdings plc Temel Bilgiler Özeti

Freeline Therapeutics Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
78F0 temel i̇stati̇sti̇kler
Piyasa değeri	€16.41m
Kazançlar(TTM)	-€55.72m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.3x

F/K Oranı

78F0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
78F0 gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$61.07m
Kazançlar	-US$61.07m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-14.06
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

78F0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

78F0 Stoklara Genel Bakış

Ödüller

Risk Analizi

Freeline Therapeutics Holdings plc Rakipler

XTRA:MDG1

€31.0m

XTRA:CNW

€6.5m

XTRA:2INV

€60.4m

DB:VSC

€56.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Recent updates

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company